SGLT2 inhibitors and finerenone in non-diabetic CKD: a step into the (near) future?

被引：1
|
作者：
Theodorakopoulou, Marieta P. [1 ]
Sarafidis, Pantelis [1 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Nephrol 1, Thessaloniki, Greece
来源：
CLINICAL KIDNEY JOURNAL | 2024年 / 17卷 / 01期
关键词：
CHRONIC KIDNEY-DISEASE;
D O I：
10.1093/ckj/sfad272
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Elucidation of the Renoprotective Effects of SGLT2 Inhibitors in Nondiabetic CKD
    Hirano, Akira
    Kidokoro, Kengo
    Kishi, Seiji
    Nagasu, Hajime
    Sasaki, Tamaki
    Kashihara, Naoki
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [32] Safety of SGLT2 Inhibitors in CKD Walking the Fine Line
    Dobre, Mirela
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 17 (06): : 774 - 776
  • [33] Glycemic Variability after Initiation of SGLT2 Inhibitors in CKD
    Tang, Mengyao
    De Boer, Ian
    Kalim, Sahir
    DIABETES, 2024, 73
  • [34] SGLT2 Inhibitors and Mortality Risk in Individuals with Advanced CKD
    Issa, Rochell
    Dobre, Mirela A.
    Makhlouf, Mohamed
    Negrea, Lavinia Aura
    Brateanu, Andrei
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [35] SGLT2 inhibitors: approved for adults and cats but not for children with CKD
    Gross, Oliver
    Haffner, Dieter
    Schaefer, Franz
    Weber, Lutz T.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 (06) : 907 - 909
  • [36] Real-Life Experience on the Effect of SGLT2 Inhibitors vs. Finerenone vs. Combination on Albuminuria in CKD
    Hanouneh, Mohamad A.
    Le, Dustin
    Tamargo, Christina Lauren
    Jaar, Bernard G.
    Cervantes, C. Elena
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [37] Extending the ambit of SGLT2 inhibitors beyond diabetes: a review of clinical and preclinical studies on non-diabetic kidney disease
    Nayak, Saurabh
    Rathore, Vinay
    Bharati, Joyita
    Sahu, Kamal Kant
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (12) : 1513 - 1526
  • [38] Safety and efficacy of SGLT2 inhibitors in diabetic and non-diabetic heart failure patients, a meta-analysis of randomized controlled trials
    Awad, A. K.
    Hasan, M. Tarek
    Shih, M.
    Attia, A. N.
    Aboeldahab, H.
    Bendary, M.
    Bendary, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 941 - 941
  • [39] Benefits of the Sglt2 Inhibitor Empagliflozin on Epicardial Adipose Tissue in Non-Diabetic Hfref
    Santosgallego, Carlos G.
    Requena-Ibanez, Juan Antonio
    Botija, Maria Belen Picatoste
    Ishikawa, Kiyotake
    Sanz, Javier
    Fuster, Valentin
    Badimon, Juan J.
    CIRCULATION, 2022, 146
  • [40] FINERENONE ADDED TO RAS/SGLT2 BLOCKADE FOR NON-DIABETIC CHRONIC KIDNEY DISEASE: RESULTS OF A PRECLINICAL DOUBLE-BLINDED RANDOMIZED CONTROLLED TRIAL
    Zhu, Zhihui
    Kusunoki, Yoshihiro
    Rosenkranz, Karoline
    Li, Chenyu
    Klaus, Martin
    Gross, Oliver
    Angelotti, Maria Lucia
    Cirillo, Luigi
    Romagnani, Paola
    Buelow, Roman David
    Boor, Peter
    Anders, Hans-Joachim
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I51 - I52
12345